Compliance with tamoxifen in women with breast cancer and a BRCA1 or BRCA2 mutation

Journal of Clinical Oncology

Volumn 28, Issue 33, 2010, Pages

  Narod, Steven A ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; TAMOXIFEN;

BREAST CANCER; CANCER CHEMOTHERAPY; GENE MUTATION; HUMAN; LETTER; PATIENT COMPLIANCE; PREMENOPAUSE; PRIORITY JOURNAL; TREATMENT DURATION;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; FEMALE; GENES, BRCA1; GENES, BRCA2; HUMANS; MEDICATION ADHERENCE; MUTATION; TAMOXIFEN;

EID: 79951888675     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.31.5770     Document Type: Letter

References (2)

1. Gronwald J, Tung N, Foulkes WD, et al: Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: An update. Int J Cancer 118:2281-2284, 2006
2. Hershman DL, Kushi LH, Shao T, et al: Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancers. J Clin Oncol 28:4120-4128, 2010